Skip to main content

Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

  • Poster presentation
  • Open access
  • Published:

Cish attenuates proximal TCR-signaling and CD8+ T cell immunity

CD8+ T cells are potent killers of infected cells and tumors, specifically recognizing their targets through the T cell receptor (TCR). While much has been revealed about the activation of TCR signaling, negative regulation of this pathway remains incompletely elucidated. We report that Cish plays an inhibitory role in immunity to infection and adoptive transfer of Cish-deficient CD8+ T cells eliminated established cancer. Cish deletion resulted in augmented acute phospholipase Cg1 (PLCg1) activation, Ca2+ flux, NFAT and NFkB activity, and cytokine release. Conversely, Cish reconstitution decreased Ca2+ flux, T cell polyfunctionality and PLCg1 accumulation in microclusters. We found that Cish physically interacts with PLCg1, targeting it for degradation following TCR engagement. Our data reveals a central role for Cish as a negative regulator of proximal TCR signaling and CD8+ T cell immunity and identifies a new targetable interaction for immune-based therapy of infectious disease and cancer.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palmer, D., Guittard, G., Patel, S. et al. Cish attenuates proximal TCR-signaling and CD8+ T cell immunity. j. immunotherapy cancer 2 (Suppl 3), P32 (2014). https://doi.org/10.1186/2051-1426-2-S3-P32

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2051-1426-2-S3-P32

Keywords